Clinical trials: FDC
Pancreatic Neoplasms
Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer
The overall purpose of this research is to evaluate the safety and toxicity of an investigational medication, IMP321, in patients being treated with gemcitabine.
- Trial name
- NCT00732082
- Testing
- Gemcitabine, LAG-3
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
The aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally…
- Trial name
- NCT04080804
- Testing
- Nivolumab, Relatlimab, Ipilimumab
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Dan Zandberg
HIV Infections
Women in Dual With Dolutegravir
Strategies for optimizing antiretroviral treatment in virologically suppressed patients are still a major challenge in the field of HIV.
- Trial name
- Woddol4455 (NCT05735535)
- Testing
- Antiviral Agents
- Where
- Italy
- Volunteers
- 290 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Symptomatic Genetic Dilated Cardiomyopathy (DCM)
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Danicamtiv is an investigational medication, which means it is still being studied and has not been approved. The purpose of this study is to learn how well danicamtiv works, how safe it is, how well people can take it when used…
- Trial name
- KINSHIP-OLE (NCT07771465)
- Testing
- Danicamtiv
- Where
- 78 sites in United States, Belgium and 9 more
- Volunteers
- 332 people
- Sponsor
- Kardigan, Inc.
NSCLC, Locally Advanced
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced…
- Trial name
- TRIPL (NCT06865339)
- Testing
- Cemiplimab, Fianlimab, Radiotherapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Montefiore Medical Center
HIV-1 Infection
Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
The primary objective of the study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) after switching from a stable regimen consisting of…
- Trial name
- NCT02616029
- Testing
- E/C/F/TAF
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 66 people
- Sponsor
- Gilead Sciences
Breast Carcinoma
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy
The goal of this clinical trial is to compare the safety and efficacy of eftilagimod alpha (efti) in combination with paclitaxel standard of care chemotherapy in participants with metastatic breast cancer.
- Trial name
- AIPAC-003 (NCT05747794)
- Testing
- eftilagimod alpha, Paclitaxel
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 72 people
- Sponsor
- Immutep S.A.S.
Hypertension
PK Study of YH22162 FDC Compared to Combination of Twynsta and Hygroton
This is a Randomized, open-label, single-dose, 2-treatment, 2-period, 2-sequence crossover design.
- Trial name
- NCT02496910
- Testing
- YH22162, Telmisartan/Amlodipine 80/5 mg (FDC), Chlorthalidone 25mg
- Where
- South Korea
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Volunteers
Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers
The purpose of this study is to compare pharmacokinetics and safety of Irbesartan High and Amlodipine Fixed Dose Combination and coadministration of mono compounds in healthy adult volunteers
- Trial name
- NCT05688085
- Testing
- Irbesartan High/Amlodipine FDC, Irbesartan High, Amlodipine
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
Healthy Subjects in Fasted and Fed State
The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions
This is a bioequivalence study of two doses of the dapagliflozin/metformin XR tablet manufactured at two different plants.
- Trial name
- NCT03216278
- Testing
- Dapagliflozin/metformin XR 5/500mg, Dapagliflozin/metformin XR 5/500 mg, Dapagliflozin/metformin XR 10/1000mg
- Where
- Brazil
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypertension
Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.
This is a randomized, open-label, single-dose, period-balanced, three-period crossover study conducted in healthy subjects designed to evaluate whether the absorption of the FDC formulation is affected by the ingestion of a high…
- Trial name
- NCT00557128
- Testing
- COREG CR and lisinopril (FDC)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Metastatic Breast Cancer
A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel
This is a multicentre, multinational Phase Ib study in female HR+ MBC patients not receiving Her2-targeted therapy. Treatment consists of a chemo-immunotherapy phase followed by a maintenance phase.
- Trial name
- AIPAC-002 (NCT04252768)
- Testing
- Eftilagimod Alpha, Paclitaxel
- Sponsor
- Immutep S.A.S.
Metastatic Cancer, Solid Tumor
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
The primary purpose of this study is to see if Sym021 is safe and tolerable as monotherapy, in combination with either Sym022 or Sym023, and in Combination with both Sym022 and Sym023 for patients with locally…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03311412
- Testing
- Sym021, Sym022, Sym023
- Where
- 4 sites in United States, Canada
- Volunteers
- 89 people
- Sponsor
- Symphogen A/S
Colorectal Cancer
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of cemiplimab and the combination of cemiplimab/fianlimab in microsatellite unstable localized or locally advanced colorectal cancer diagnosed in patients…
- Trial name
- NCT06205836
- Testing
- Cemiplimab, Fianlimab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Diabetes Mellitus, Type II
Bioequivalence Study for Acarbose / Metformin FDC
To establish the bioequivalence between Acarbose / Metformin FDC (50mg / 500mg) and loose combination of Acarbose (Glucobay) (50mg) and Metformin (Glucophage) (500mg).
- Trial name
- NCT01728740
- Testing
- Acarbose/Metformin FDC (BAY81-9783), Acarbose (Glucobay, BAYG5421), Metformin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
HIV, HIV Infections
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
The primary objective of this study is to evaluate the non-inferiority of switching to a tenofovir alafenamide (TAF)-containing fixed dose combination (FDC) relative to maintaining tenofovir disoproxil fumarate (TDF)-containing…
- Trial name
- NCT01815736
- Testing
- E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF
- Where
- 167 sites in United States, Australia and 18 more
- Volunteers
- 1,443 people
- Sponsor
- Gilead Sciences
Bioequivalence
Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants
The purpose of this study is to evaluate the bioequivalence of metformin component of the canagliflozin and metformin immediate release (IR) fixed dose combination (FDC) tablet compared with the metformin IR tablet…
- Trial name
- NCT02221180
- Testing
- Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC], Canagliflozin, Metformin
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes
Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)
This study is designed to investigate the food-effects on FDC(gemigliptin/metformin HCl sustained release) 50/1000mg(25/500mg x 2tablets)
- Trial name
- NCT01747083
- Testing
- FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Hypertension
Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
This is a randomized, comparative Phase 3 trial to investigate the efficacy of fixed dose combination (FDC) of bisoprolol and amlodipine in hypertensive subjects (superiority of FDC over monotherapies).
- Trial name
- NCT01977794
- Testing
- Bisoprolol/Amlodipine (Bisoprolol failed group), Bisoprolol/Amlodipine (Amlodipine failed group)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Merck KGaA, Darmstadt, Germany